Determining programmed cell death ligand 1 expression in circulating tumor cells of patients with clear cell renal cell carcinoma and its correlation with response to programmed cell death protein 1 inhibitors.
Bo-Han ChenChien-Chang KaoTing XuYung-Ning YangTai-Lung ChaYi-Ta TsaiShu-Yu LiuSheng-Tang WuEn MengChih-Wei TsaoChin-Li ChenGuang-Huan SunDah-Shyong YuSun-Yran ChangMing-Hsin YangPublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
We showed that the presence of programmed cell death ligand 1 + circulating tumor cells before programmed cell death protein 1 inhibition treatment could be a prognosis predictive factor and that the dynamic changes in circulating tumor cell numbers may be used to monitor the therapeutic response. Our study confirms the possibility of programmed cell death ligand 1 + circulating tumor cell detection in clear cell renal cell carcinoma patients' blood samples, which can potentially be used as an individualized immunotherapy molecular biomarker for real-time exploration.
Keyphrases
- circulating tumor cells
- circulating tumor
- single cell
- end stage renal disease
- cell therapy
- cell free
- poor prognosis
- binding protein
- newly diagnosed
- chronic kidney disease
- ejection fraction
- prognostic factors
- protein protein
- amino acid
- stem cells
- small molecule
- single molecule
- long non coding rna
- quantum dots
- smoking cessation